Forefront Collaborative | Current Controversies in Dyslipidemia Management: A Point-Counterpoint Discussion
Sometimes current topics in the treatment space are best understood through discussion. Sometimes they’re best served through rigorous debate. When it comes to the current controversies and questions related to the management of dyslipidemia, the latter approach offers something more. Harnessing both the passion and scientific acumen of the HCP community, we collaborated with the National Lipid Association to orchestrate a series of point-counterpoint exchanges between leading experts focusing on several critical questions, including the role of guidelines and recommendations in the treatment of individual patients with dyslipidemia and the utility of lipid goals and threshold treatment values. Breaking it down further, additional topics included residual risk, the impact of statin trial study designs as they relate to atherosclerotic cardiovascular disease (ASCVD) outcomes and lipid goals, and the role of HDL-C in ASCVD risk and whether it is a viable lipid treatment target. Guided by the educational strategies rooted in current CME/CPD best practices and adult learning principles, this lively educational activity sought to provide the best available evidence in order to guide large groups of learners-- clinical cardiologists, primary care clinicians, physician assistants, pharmacists, advance practice registered nurses, registered nurses, and registered dietitians with patients with dyslipidemia and risk for ASCVD–toward incorporating new information and medications into their clinical decision-making in a safe and effective way. Supported by an educational grants from Lilly and Sanofi, these lively symposiums are accessible on myCME. To get in on the discussion, click here.
Dyslipidemia, Forefront, guidelines, atherosclerotic, cardiovascular, disease, ASCVD, lipid,
16904
post-template-default,single,single-post,postid-16904,single-format-standard,,qode-title-hidden,qode_grid_1200,footer_responsive_adv,qode-theme-ver-9.1.2,wpb-js-composer js-comp-ver-4.11.2,vc_responsive

12 Aug Current Controversies in Dyslipidemia Management: A Point-Counterpoint Discussion

Dyslipidemia / Live Meeting at NLA 

Sometimes current topics in the treatment space are best understood through discussion. Sometimes they’re best served through rigorous debate. When it comes to the current controversies and questions related to the management of dyslipidemia, the latter approach offers something more. Harnessing both the passion and scientific acumen of the HCP community, we collaborated with the National Lipid Association to orchestrate a series of point-counterpoint exchanges between leading experts focusing on several critical questions, including the role of guidelines and recommendations in the treatment of individual patients with dyslipidemia and the utility of lipid goals and threshold treatment values. Breaking it down further, additional topics included residual risk, the impact of statin trial study designs as they relate to atherosclerotic cardiovascular disease (ASCVD) outcomes and lipid goals, and the role of HDL-C in ASCVD risk and whether it is a viable lipid treatment target. Guided by the educational strategies rooted in current CME/CPD best practices and adult learning principles, this lively educational activity sought to provide the best available evidence in order to guide large groups of learners– clinical cardiologists, primary care clinicians, physician assistants, pharmacists, advance practice registered nurses, registered nurses, and registered dietitians with patients with dyslipidemia and risk for ASCVD–toward incorporating new information and medications into their clinical decision-making in a safe and effective way. Supported by educational grants from Lilly and Sanofi, these lively symposiums are accessible on myCME.

To get in on the discussion, click here.